Clinical Trial Search

Primary: Number of Participants With Voluntary Movement — 1; 0 Participants

Primary: Count to Achieve Mobility Skills — 9; 3; 0; 10 Participants

Primary: Safety-Number of Adverse Events — 69 Adverse events

Primary: Grasp Release Test - Test of Functional Ability to Pick up and Move Objects — 2; 5.5 Number of Completions

Primary: Arm and Hand Function as Assessed by Score on the Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) — 64.9; 58.3 score on a scale

Primary: Improvement on the MCS in All Randomized Participants — 12; 14 Participants — p=0.798

Primary: Muscle Mass Via Dual-Energy X-ray Absortiometry (DEXA)Scan Data — 6104.45; 6355.3 grams — p=.318

Primary: Change in Motor Evoked Potential (MEP) Amplitude in the Tibialis Anterior Muscle at the End of Training. — -1.75; -2.01 Amplitude percentage of Mmax

Primary: Change in % Body Fat — -1.83; -1.68 Percent Body Fat — p=>0.05

Primary: Barriers to Physical Activity Questionnaire for People With Mobility Impairments (BPAQ-MI) — 0.66; 1.24; 0.22; 0.06 units on a scale

Primary: Graded and Redefined Assessment of Strength, Sensibility and Prehension Test (GRASSP Test) — 4.5; 19.4 score change before and after — p=<0.000

Primary: Electromyography — 0.00017507; 0.00006740 volts

Primary: Standing Performance — 27.4; 15.6 minutes

Primary: Pinch Force — 8.7; 10.6 newtons

Primary: Number of Participants Demonstrating 10% Change: Arm Ergometer and Lokomat Metabolic Cart VO2 Peak — 17; 13; 17; 12 participants

Primary: Physiological Cost Index (PCI) Ratio — 3.34 unit less

Primary: Mean Arterial Blood Pressure in Response to Epidural Stimulation — 112.5 mmHg

Primary: Change in Voluntary Movement — 2; 0 Participants

Primary: Change in Motor and Sensory Scores of the ASIA Impairment Scale (AIS) — 1.0; 2.7; 2.4; -1.2 scores on AIS Scale

Primary: 10-meter Walking Speed (m/Sec) — 0.165; 0.215; 0.13; 0.13 speed (m/sec)

Primary: Gait Speed With 10-Meter Walk Test — -10.24; -1.79 seconds — p=0.006

Primary: Incidence of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 5; 6 Participants

Primary: Change in Core Body Temperature — -0.24; -0.97; NA; 0.79 °C — p=<0.001

Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline

Primary: Double-blind Change From Baseline in Ashworth Score Evaluating Spasticity — -0.19; -0.15 units on a scale

Primary: Oxygen Consumption — 625 VO2 (ml/min)

Primary: Percent Change in Hmax — 27.85; 8.43; -4.91; 16.20 percent change in Hmax

Primary: 10 Meter Walking at Preferred Speed — 0.04; 0.06 meters per second

Primary: Change in Walking Function - 10m Walk Walking Speed (m/s) — 0.06; 0.16 speed difference in meters per second

Primary: Walking Speed Change From Baseline — .054; .078; .085; .039 meters/second